KRAS Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings

BACKGROUND: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to epidermal growth factor receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake and utili...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Webster, Jennifer, Kauffman, Tia L., Feigelson, Heather Spencer, Pawloski, Pamala A., Onitilo, Adedayo A., Potosky, Arnold L., Cross, Deanna, Meier, Paul R., Mirabedi, Anousheh S., Delate, Thomas, Daida, Yihe, Williams, Andrew E., Alexander, Gwen L., McCarty, Catherine A., Honda, Stacey, Kushi, Lawrence H., Goddard, Katrina A.B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567775/
https://ncbi.nlm.nih.gov/pubmed/23155138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-12-0545
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi